Alto Neuroscience, Inc. ANRO 深 滬
交易中 09-10 11:58:18 美东时间
3.5499
-0.220
-5.84%
華盛通- 最 高3.75
- 今 開3.75
- 成交量 3.38万股
- 最 低 3.50
- 昨 收 3.77
- 總市值 9610.32万
- 52周最高 15.04
- 市盈率 靜 --
- 換手率 0.12%
- 52周最低 1.60
- 委 比 66.67%
- 總股本 2707.21万
- 歷史最高 24.00
- 量 比 1.85
- 振 幅 6.63%
- 歷史最低 1.60
- 每 手 1
- 風險率 3.34%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Alto Neuroscience Reports Replication Study Results Validating EEG Biomarkers in Schizophrenia
Alto Neuroscience, Inc. ("Alto") (NYSE:ANRO) a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today announced positive results from an
09-09 19:16
美股大行评级 | 财报前夕，家得宝、劳氏、沃尔玛分别获大行上调目标价！瑞银下调赛富时目标价至260美元
今日重点评级关注：Craig-Hallum：维持Applied Digital"买入"评级，目标价从12美元升至23美元；HC Wainwright & Co.：维持Bitdeer Technologies"买入"评级，目标价从18美元升至19美元
08-19 09:56
HC Wainwright & Co. Reiterates Buy on Alto Neuroscience, Maintains $10 Price Target
HC Wainwright & Co. analyst Patrick R. Trucchio reiterates Alto Neuroscience (NYSE:ANRO) with a Buy and maintains $10 price target.
08-19 01:11
Alto Neuroscience Advances Pipeline Amidst Strong Cash Position
Alto Neuroscience, Inc. ( ($ANRO) ) has released its Q2 earnings. Here is a bre...
08-14 12:31
Alto Neuroscience GAAP EPS of -$0.65
Alto Neuroscience press release (NYSE:ANRO): Q2 GAAP EPS of -$0.65. As of June 30, 2025 the Company had cash, cash equivalents, and restricted cash of approximately $148.1 million, compared to approxi...
08-14 04:46
Alto Neuroscience Q2 EPS $(0.65) Misses $(0.61) Estimate
Alto Neuroscience (NYSE:ANRO) reported quarterly losses of $(0.65) per share which missed the analyst consensus estimate of $(0.61) by 7.08 percent. This is a 8.33 percent decrease over losses of $(0.60) per share from
08-14 04:25
美股大行评级 | 潜在涨幅205.56%！康托·菲茨杰拉德上调HIVE Digital Technologies目标价至5.5美元，维持"超配"评级
<span> <meta content="no-referrer" name="referrer"></span><p>https://static-hk.hstong.com/public/forum-v2/status/icon/50267976/originalpic/1145638202455883776.png</p><span style="color:#999999;">编者按：每日追踪华尔街最新评级与目标价，挖掘潜力股投资机会。</span><blockquote> <p><span style="color:#fa1432;"><strong>今日重点评级关注</strong></span></p></blockquote><p>• 康托·菲茨杰拉德：维持HIVE Digital Technologies(HIVE)"超配"评级，目标价从5美元升至5.5美元</p> <p>• BTIG：维持Theravance Biopharma(TBPH)"买入"评
06-28 08:37
美股大行评级 | 潜在涨幅61.27%！Loop Capital上调英伟达目标价至250美元，维持"买入"评级
今日重点评级关注：Benchmark：维持特斯拉(TSLA)"买入"评级，目标价从350美元升至475美元>>
06-27 08:37
Alto Neuroscience Identifies EEG Biomarker And Reports Pharmacodynamic Results From Phase 2 Trial Of ALTO-203 For Major Depressive Disorder
Demonstrated target engagement and response prediction for ALTO-203 by theta/beta ratio, a commonly used EEG index of cortical arousal and attentional control ALTO-203, a non-stimulant compound which demonstrated
06-26 19:37
Alto Neuroscience Acquires Assets from Chase Therapeutics
An announcement from Alto Neuroscience, Inc. ( ($ANRO) ) is now available. On M...
06-03 18:58
